NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first-time in India under the brand name Tipanat as a pack of 20 tablets in a bottle. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

In India, approximately 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending the survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. NATCO has offered Tipanat at an affordable price.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 821.30 as compared to the previous close of Rs. 832.65. The total number of shares traded during the day was 5872 in over 654 trades.

The stock hit an intraday high of Rs. 832.95 and intraday low of 818.80. The net turnover during the day was Rs. 4849349.00.

Source : Equity Bulls

Keywords

NatcoPharmaLimited INE987B01026 Pharmaceuticals Tipanat Trifluridine Tipiracil FixedDose ColorectalCancer GastricCancer